The Next Frontier: Industrializing Cell Therapy Manufacturing 5/10/2024

AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.

GLP-1s Like Novo Nordisk’s Ozempic Do Not Increase Thyroid Cancer Risk: Study 4/10/2024

AACR: Merck, Kelun’s Anti-TROP2 ADC Shows Early Promise in Gastric Cancer 4/10/2024

TORL Targets Hot ADC Space with Oversubscribed $158M Series B-2 4/10/2024

Birth Control Market Evolves as OTC Opill Hits US Stores 4/10/2024

Can $12 Billion Jumpstart Women’s Health? 4/10/2024

Alphabet Soup: AACR and ACC Dominate Headlines This Week 4/10/2024

YS Biopharma’s Rabies Vaccine Outperforms Commercial Competitor in Phase III Trial 4/10/2024

AACR: Study Suggests Accelerated Approval Doesn’t Always Lead to Clinical Benefit 4/10/2024

7 Billion-Dollar Oncology M&As from Q1 4/10/2024

The IRA Is Already Curtailing Small Molecule Drug Development. Here’s How to Reverse That. 4/10/2024

Poor Customer Data Management Costs Pharma Companies Money: Report 4/10/2024

AACR 2024: What Cancer Researchers Are Talking About 4/10/2024

Some proteins in the human body are easy to block with a drug; they have an obvious spot in their structure where a drug can fit, like a key in a lock. But other proteins are more difficult to target, with no clear drug-binding sites.

To design a drug that blocks a cancer-related protein, Scripps Research scientists took a hint from the protein's paralog, or "twin."

Glioblastoma is one of the most serious brain diseases known. More than 45% of brain cancers are gliomas. Only half of glioblastoma patients respond to the FDA-approved chemotherapy Temozolomide (TMZ). Even for those patients, the cancer cells quickly evolve resistance. Most patients pass away within 12 to 16 months after diagnosis, and few make it beyond five years.

Now a glimmer of hope for patients comes from an unlikely place: Jackson Hole, Wyoming, where scientists at the non-profit Brain Chemistry Labs have been studying molecules found in violets.

More than one-third of adults in the United States have metabolic syndrome, a cluster of conditions that significantly raise a person's risk of heart disease, stroke, and type 2 diabetes. These conditions include high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol levels.

In a new clinical trial, researchers at the Salk Institute and University of California San Diego School of Medicine found that time-restricted eating - also known as intermittent fasting - could offer significant health benefits to adults with metabolic syndrome.

Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG announced positive 24-month data from exPDite, a Phase 1 clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease.

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson's disease.

In 2022, nearly 619,000 global deaths due to malaria were caused by Plasmodium falciparum, the most virulent, prevalent, and deadly human malaria parasite. For decades, the parasite's resistance to all antimalarial drugs has posed a big challenge for researchers working to stop the spread of the disease.

A team led by scientists at UC Riverside, UC Irvine, and Yale School of Medicine has now designed a new drug against malaria and identified its mechanism of action.

Bayer announced today the inauguration of its new life science incubator, Bayer Co.Lab Shanghai, in the Shanghai Innovation (SH-INNO) Park at the heart of China's largest biopharma cluster, Zhangjiang, Shanghai. Bayer Co.Lab is part of the global network of life science incubators situated in key innovation hubs, including Cambridge (USA), Kobe (Japan), and Berlin (Germany). The establishment of Bayer Co.Lab Shanghai represents a major milestone in Bayer's external innovation strategy, aimed at fostering open collaboration within the biotechnology ecosystem.